The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 28, 2016
Filed:
Jul. 31, 2015
Applicant:
Centre National DE LA Recherche Scientifique, Paris, FR;
Inventors:
Petrus Johannes Louis Spee, Allerød, DK;
Peter Andreas Nicolai Reumert Wagtmann, Rungsted Kyst, DK;
Stefan Zahn, Ballerup, DK;
Elisabeth D. Galsgaard, Naerum, DK;
Birgitte Friedrichsen, Gentofte, DK;
Véronique Braud, Grasse, FR;
Assignee:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris, FR;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/18 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2851 (2013.01); C07K 16/18 (2013.01); G01N 33/6872 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract
The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.